Pharmacovigilance, regulatory affairs and IT services will be added to clinical service company Bioclinica’s pharma and biotech offerings through the acquisition of Miami, Florida-based Synowledge, announced today.
“Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events,” Bioclinica CEO John Hubbard said in a statement today.
“Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.”
Synowledge employs over 500 staff in offices in North America, Europe, India, and Japan, and Sankesh Abbhi - the company’s founder – expressed his pleasure at joining Bioclinica.
“Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.”
Abbhi will serve as senior vice president and head of global safety and regulatory solutions at the merged entity.
The news is the latest in a series of expansions at Bioclinica. In July the firm added patient recruitment and retention services through the acquisition of MediciGroup, days after announcing it had opened offices in London and Munich to support its imaging services.